scholarly journals Multiple Myeloma Involving Left Hemicranium

2022 ◽  
Author(s):  
Jutty Parthiban ◽  
B. Udaykumar ◽  
Sudeendra Reddy Peddireddy ◽  
Balasubramaniam Prakash ◽  
Vighnesh Kandha Kumar
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Malignant Neoplasm ◽  
Brain Parenchyma ◽  
Intracranial Extension ◽  
Parietal Region ◽  
Skull Bone ◽  
X Ray ◽  
Mri Brain ◽  
Ct And Mri

AbstractMultiple myeloma (MM) is a malignant neoplasm of bone marrow affecting plasma cells. It is commonly seen as multiple punched-out lesions in the skull bone as a characteristic feature. Its presentation as hemicranial involvement with intracranial extension is rare. A 46-year-old male presented with left side scalp swelling, prominent over parietal region. X-ray showed multiple punched out lesions involving left hemicranium. CT and MRI brain showed intracranial extension of lesion without brain parenchyma invasion. He was treated with biopsy of lesion followed by chemotherapy.

scholarly journals A case of multiple myeloma presenting as scalp swelling with intracranial extension

2013 ◽  
Vol 04 (04) ◽  
pp. 445-448 ◽  
Author(s):  
Satya Bhusan Senapati ◽  
Sudhansu Sekhar Mishra ◽  
Manmath Kumar Dhir ◽  
Srikanta Das ◽  
Kalpalata Tripathy
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cells ◽  
Bone Erosion ◽  
Malignant Lesion ◽  
Malignant Neoplasm ◽  
Intracranial Extension ◽  
Histopathological Study ◽  
Skull Bone ◽  
Characteristic Features

ABSTRACTMultiple myeloma is a malignant neoplasm of bone marrow affecting plasma cells. It is usually detected in skull bone with characteristic features of multiple punched-out lesions. Its presentation as a solitary scalp swelling with underlying skull bone erosion and intracranial extension is very rare. A 35-year-old female presented to us with complains of rapidly growing left-side scalp swelling with right-side paresis and simple partial seizure of right upper limb. Local examination, X-ray skull, CT scan, and MRI of brain were suggestive of a malignant lesion. Near total excision of lesion was done. Histopathological study was suggestive of plasmacytoma of skull. Bone marrow study further confirmed it as a case of multiple myeloma. Cases presenting with solitary osteolytic skull lesions, possibility of plasmacytoma, or multiple myeloma should be kept in mind.

scholarly journals Recurrent Malignant Fibrous Histiocytoma in the Left Parietal Region of Cranium: A Case Report

1970 ◽  
Vol 17 (1) ◽  
pp. 55-56
Author(s):  
ML Rahman ◽  
ASM Shawkat Ali
Keyword(s):  
Malignant Fibrous Histiocytoma ◽  
Fibrous Histiocytoma ◽  
Brain Parenchyma ◽  
Parietal Region ◽  
Skull Bone ◽  
Previous Surgery ◽  
History Of ◽  
One Year ◽  
The Brain ◽  
Space Occupying Lesion

A male of 20 years of age presented with features of intracranial space occupying lesion of cranium involving the brain. He came with the history of previous surgery in the head one-year back. On operation, an osteolytic growth from the skull bone invading the meninges and brain parenchyma. Who found Histopathological report revealed malignant fibrous histiocytoma.   doi: 10.3329/taj.v17i1.3492 TAJ 2004; 17(1) : 55-56

scholarly journals Genome Instability in Multiple Myeloma: Facts and Factors

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5949
Author(s):  
Anna Y. Aksenova ◽  
Anna S. Zhuk ◽  
Artem G. Lada ◽  
Irina V. Zotova ◽  
Elena I. Stepchenkova ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Complex Disease ◽  
Plasma Cells ◽  
Genome Instability ◽  
Hematologic Malignancy ◽  
Point Mutations ◽  
Malignant Neoplasm ◽  
Chemotherapeutic Agents ◽  
Hematopoietic Stem ◽  
Social Burden

Multiple myeloma (MM) is a malignant neoplasm of terminally differentiated immunoglobulin-producing B lymphocytes called plasma cells. MM is the second most common hematologic malignancy, and it poses a heavy economic and social burden because it remains incurable and confers a profound disability to patients. Despite current progress in MM treatment, the disease invariably recurs, even after the transplantation of autologous hematopoietic stem cells (ASCT). Biological processes leading to a pathological myeloma clone and the mechanisms of further evolution of the disease are far from complete understanding. Genetically, MM is a complex disease that demonstrates a high level of heterogeneity. Myeloma genomes carry numerous genetic changes, including structural genome variations and chromosomal gains and losses, and these changes occur in combinations with point mutations affecting various cellular pathways, including genome maintenance. MM genome instability in its extreme is manifested in mutation kataegis and complex genomic rearrangements: chromothripsis, templated insertions, and chromoplexy. Chemotherapeutic agents used to treat MM add another level of complexity because many of them exacerbate genome instability. Genome abnormalities are driver events and deciphering their mechanisms will help understand the causes of MM and play a pivotal role in developing new therapies.

Tooth Extraction Locally Stimulates Proliferation of Multiple Myeloma in a Patient with Mandibular Localizations

2017 ◽  
Vol 138 (4) ◽  
pp. 201-207 ◽  
Author(s):  
Jean-Daniel Kün-Darbois ◽  
Léonie Quenel ◽  
Smaïl Badja ◽  
Daniel Chappard
Keyword(s):  
Multiple Myeloma ◽  
Tooth Extraction ◽  
Soft Tissues ◽  
Plasma Cells ◽  
Osteonecrosis Of The Jaw ◽  
Surgical Trauma ◽  
Osteolytic Lesions ◽  
X Ray ◽  
Extraction Site ◽  
The Right

Objectives: Multiple myeloma (MM) is characterized by the occurrence of osteolytic lesions. MM treatment usually involves antiresorptive drugs (mainly bisphosphonates). Case Report: A patient with an MM presented osteolytic lesions of the mandible. Extraction of teeth 45 and 46 was performed 5 years after the diagnosis of periodontitis. Four months later, osteonecrosis of the jaw (ONJ) was diagnosed at the extraction site. X-ray showed an extension of osteolytic lesions on the right side, close to the extraction site, without modification of the lesions on the left side. Two months later, a curettage was performed because of a painful bone sequestration. X-ray showed an extension of the osteolytic lesions on the right side. Results: Histological analysis found a vascularized plasmacytoma of the soft tissues around the ONJ. Analysis of the bone showed mixed lesions with osteonecrotic areas and living bone resorbed by active osteoclasts surrounding a plasmacytoma. The surface area of the osteolytic foci has considerably increased only close to the extraction site. Conclusions: Tooth extraction triggered an ONJ associated with bisphosphonate treatment. However, it also seemed to induce a considerable proliferation of plasma cells at the extraction site; we hypothesize that it is due to the increase in bone remodeling related to the surgical trauma.

scholarly journals Maxillary Swelling as the First Evidence of Multiple Myeloma

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Atsushi Kasamatsu ◽  
Yasushi Kimura ◽  
Hideki Tsujimura ◽  
Harusachi Kanazawa ◽  
Nao Koide ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Malignant Neoplasm ◽  
Magnetic Resonance Images ◽  
Oral Manifestations ◽  
Tissue Mass ◽  
Old Japanese ◽  
Single Clone ◽  
Buccal Space ◽  
The Right

Multiple myeloma is a malignant neoplasm of plasma cells characterized by proliferation of a single clone of abnormal immunoglobulin-secreting plasma cells. Since the amount of hemopoietic bone marrow is decreased in the maxilla, oral manifestations of multiple myeloma are less common in the maxilla than in the mandible. We report the case of 33-year-old Japanese man who presented with a mass in the right maxillary alveolar region. Computed tomography and magnetic resonance images showed a soft tissue mass in the right maxilla eroding the anterior and lateral walls of the maxillary sinus and extending into the buccal space. The biopsy results, imaging, and laboratory investigations led to the diagnosis of multiple myeloma. This case report suggests that oral surgeons and dentists should properly address oral manifestations as first indications of multiple myeloma.

scholarly journals Multiple Myeloma - Atypical Presentation - Clinicopathological Correlation

2021 ◽  
Vol 10 (40) ◽  
pp. 3526-3532
Author(s):  
Emani Usha Bhargavi ◽  
Vaddadi Suresh
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cells ◽  
Wide Spectrum ◽  
Case Series ◽  
Malignant Neoplasm ◽  
Routine Practice ◽  
Cutaneous Lesions ◽  
Clinical Presentations ◽  
Case Series Study

BACKGROUND Multiple myeloma, malignant neoplasm of plasma cells producing monoclonal para protein is one of the most common haematological malignancies we see in our routine practice. Multiple myeloma has varied and diverse clinical presentations, of which most common clinical features will be anaemia, bone pain, fever, fatigue, weight loss, paraesthesia, renal failure, pathological fractures, cutaneous lesions, etc. We hereby, present a series of multiple myeloma cases with unusual presentation over a period of 3 years. The purpose of the study was to evaluate the unusual and rare clinicohaematological presentation in patients with multiple myeloma. METHODS In this case series study, we reviewed bone marrow aspirate & / or biopsy slides in our hospital from January 2017 to January 2020. Patients diagnosed with multiple myeloma were selected. Patients’ clinical information, haematological and other findings were obtained from the medical records department and compiled, and correlation was done. RESULTS We came across a total of 9 cases of multiple myeloma with very unusual and rare clinical presentations. A thorough clinical, radiological, haematological, biochemical and histopathological correlation was done before giving a final diagnosis in these cases. Rare cutaneous and other involvement of multiple myeloma was noted. CONCLUSIONS Multiple myeloma is the most common malignancy with comparatively poor prognosis. However, early diagnosis of multiple myeloma always helps the clinician in improving the outcome and has been shown to have better prognosis. The present case series is an attempt to understand the clinico-pathological correlation, wide spectrum of clinical presentation and associated rarity of presentations. KEY WORDS Myeloma; Lytic Lesions; Bone Marrow

Multiple Myeloma Course with Renal Insufficiency in Young Patient: Case Report

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 26-26
Author(s):  
Hugo Henrique de Freitas Ferreira ◽  
Alessandra Suelen Jardim Silva ◽  
Lenilton Silva DA Silva Júnior ◽  
Gustavo Henrique de Medeiros Oliveira ◽  
Maria das Graças Pereira Araujo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Young Patient ◽  
Mononuclear Cells ◽  
Plasma Cells ◽  
Serum Proteins ◽  
Conflicts Of Interest ◽  
Young Patients ◽  
Treatment Strategies ◽  
Malignant Neoplasm

Introduction: Multiple myeloma (MM) is a malignant neoplasm characterized by the clonal proliferation of abnormal plasma cells in the bone marrow (OM). The average age of patients diagnosed with MM is approximately 70 years, being relatively uncommon in younger individuals. Objective: To report a case of a young patient with multiple myeloma. Case Description: A 42-year-old male patient presented with continuous and progressive low back pain for 3 months, associated with adynamia, weight loss (10 kg), episodes of constipation and bleeding in the oral cavity in this period. Examinations at the first appointment revealed moderate anemia (Hb 7.4 g / dL), leukocytosis, thrombocytopenia, hypercalcemia, and altered renal function (Cr 5.9 and Ur 178), chest tomography indicating vertebral fracture in T6, T11, L2 and L4. Referred for specialized follow-up, he performed electrophoresis of serum proteins with the presence of a monoclonal peak in the gamma globulin fraction. The immunofixation test confirmed monoclonality for IgA isotype and Kappa light chain (IgA / Kappa). The myelogram showed plasmacytosis of more than 50% of mononuclear cells in the bone marrow. He developed renal failure (with dosage of creatinine of 10.1 mg/ dL. and urea of 208 mg/dL) and hypercalcemia requiring dialysis therapy on the third day of hospitalization, having undergone chemotherapy with Bortezomib, cyclophosphamide and dexamethasone. During this period, infection by the multisensitive S. aureus in catheter occurred and, despite being treated with specific antibiotic therapy, it evolved with clinical worsening and hemodynamic instability and was referred to the Intensive Care Unit, going to death after 2 days. Conclusion: Young patients with MM may study with more aggressive characteristics. Despite the use of new therapeutic agents, more effective treatment strategies need to be studied more for patients in this age group. Disclosures No relevant conflicts of interest to declare.

Updates in the management of relapsed/refractory multiple myeloma

2021 ◽  
pp. 107815522110289
Author(s):  
Kirollos S Hanna ◽  
Samantha Larson ◽  
Jenny Nguyen ◽  
Sarah Tu ◽  
Jenna Boudreau ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Malignant Neoplasm ◽  
Hematologic Malignancies ◽  
The United States ◽  
Therapeutic Agents ◽  
Clinical Safety ◽  
Pharmacological Agents ◽  
Undergo Stem Cell Transplantation ◽  
Selection Of

Multiple myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy and may undergo stem cell transplantation. Despite effective therapies, multiple myeloma remains incurable. Patients often require maintenance therapy, and many will progress or relapsed following upfront treatment. Selection of treatment in the relapse/refractory setting is complex due numerous active therapeutic agents and combinations. Treatment is often tailored to prior exposure and duration. In 2020, three novel pharmacological agents were approved in the relapsed setting. We highlight the clinical safety and efficacy of selinexor, isatuximab-irfc, and belantamab mafodotin for patients with multiple myeloma.

scholarly journals Facial Swelling as a Primary Manifestation of Multiple Myeloma

2015 ◽  
Vol 2015 ◽  
pp. 1-6
Author(s):  
Anju E. Thomas ◽  
Seema Kurup ◽  
Renju Jose ◽  
Cristalle Soman
Keyword(s):  
Multiple Myeloma ◽  
Soft Tissue ◽  
Plasma Cells ◽  
Systemic Disease ◽  
Imaging Modalities ◽  
Clonal Proliferation ◽  
Dental Office ◽  
Facial Swelling ◽  
Osseous Involvement ◽  
Ct And Mri

Facial swellings are commonly encountered in the dental office, the cause of which could range from a congenital etiology to an acquired one or it may even be a manifestation of an underlying systemic disease. The clinician must have a thorough knowledge of the various clinical and imaging manifestations and the sites of occurrence of the various conditions to arrive at the appropriate diagnosis. Facial swellings can be classified into different groups which include acute swellings with inflammation, nonprogressive swellings, and slowly or rapidly progressive swellings. The various imaging modalities like CT and MRI are useful for assessing the extent of the swelling as well as evaluating the soft tissue and osseous involvement of the swelling. Multiple myeloma represents clonal proliferation of plasma cells and is a condition in which a facial swelling might be present, though not common. This paper reports a case of a patient with a unilateral facial swelling, which on investigation led to a diagnosis of multiple myeloma.

scholarly journals Treatment Approaches of Multiple Myeloma

2021 ◽  
Author(s):  
Minyahil Alebachew Woldu ◽  
Atalay Mulu Fentie ◽  
Tamrat Assefa Tadesse
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cells ◽  
Clinical Investigation ◽  
Malignant Neoplasm ◽  
Bone Destruction ◽  
Organ Damage ◽  
Autologous Stem Cell Transplant ◽  
Bone Lesions ◽  
Newly Diagnosed

Multiple Myeloma (MM) is the most common malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Clinical investigation of MM requires the evaluation of bone marrow for plasma cell infiltration, and detection and quantification of monoclonal protein in the serum or urine, and evidence for end-organ damage (i.e., hypercalcemia, renal insufficiency, anemia, or bone lesions). The overall goal of treatment of MM is to improve survival. The treatment landscape and clinical outcome of MM have changed in the last two decades, with an improved median survival of 8–10 years. Management of MM involves induction, consolidation, and maintenance therapy. Currently, Autologous stem cell transplant (ASCT) is considered as the standard care of treatment for newly diagnosed fit MM patients. Multiple combinations of proteasome inhibitors (PIs) and immunomodulatory drugs (IMIDs) such as Thalidomide, lenalidomide, and pomalidomide have been under evaluation in ASCT-eligible and ineligible settings, and studies are still ongoing. For patients with ASCT-eligible newly diagnosed MM, induction therapy with triple drugs should contain an IMiD, a PI, and a corticosteroid, usually lenalidomide-bortezomib-dexamethasone. For ASCT-ineligible patients on lenalidomide with dexamethasone (Rd), with addition of bortezomib or daratumumab can be considered.

Sign in / Sign up

Export Citation Format

Share Document